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Abstract:  29 
Despite the growing trends in the number of patients at risk for invasive fungal infections, 30 
management with current antifungal agents results in complications due to changes in the 31 
epidemiology and drug susceptibility of invasive fungal infections. In the present research 32 
fluconazole-loaded nanostructured lipid carriers were prepared using probe ultrasonication 33 
techniques and investigated the efficacy of the optimal formulation on a large number of 34 
Candida species. The morphology of the obtained nanostructured lipid carriers was characterized 35 
by transmission-electron microscopy. The minimum inhibitory concentrations (MIC) for the new 36 
formulations against strains of Candida were investigated using the Clinical and Laboratory 37 
Standards Institute document M27-A3 and M27-S4 as a guideline. The fluconazole-loaded 38 
nanostructured lipid carriers presented a spherical shape with a mean diameter, zeta potential and 39 
entrapment efficiency of 126.4 ± 15.2 nm, -35.1 ± 3.0 mV, and 93.6 ± 3.5%, respectively. The 40 
drug release from fluconazole-loaded nanostructured lipid carriers exhibited burst-release 41 
behavior at the initial stage followed by sustained release over 24 hours. Using a new 42 
formulation of fluconazole led to a significant decrease in MICs for all Candida groups (P < 43 
0.05). Furthermore, C. albicans isolates showed more susceptibility to fluconazole-loaded 44 
nanostructured lipid carriers than C. glabrata and C. parapsilosis (P < 0.05). The MIC50 drug 45 
concentration was obtained as 0.0625, 0.031 and 0.25 μg/ml for fluconazole-resistant strains of 46 
C. albicans, C. glabrata, and C. parapsilosis, respectively. In conclusion, a novel delivery 47 
system which can be used as part of a strategy to improve the antifungal activity of fluconazole 48 
against various Candida strains with different susceptibilities to conventional formulations of 49 
fluconazole was evaluated. 50 
Keywords: Fluconazole, Drug delivery, Nanostructured Lipid Carrier, Candida 51 
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1. Introduction: 52 
A variety of novel drug carrier systems have recently been proposed to improve the 53 
bioavailability and release of drugs [1]. These systems are aimed at maintaining local effects and 54 
enhancing drug accumulation in various strata of skin through liposomes or niosomes [2], gel 55 
formulation[3], lecithin-based organogel [4], hydrogel [5] or polymeric mucoadhesive films, [6] 56 
poly-lactic co-glycolic acid (PLGA) microspheres [7], solid lipid nanoparticles (SLNs) [8, 9], 57 
and nanostructure lipid carriers (NLCs) [10]. In particular, NLCs have emerged as a promising 58 
drug delivery system for pharmaceutical and cosmetic molecules, especially for the delivery of 59 
lipophilic compounds.[11-13] Briefly, NLCs are colloidal nanocarriers in the submicron range 60 
(40 to 1000 nm) composed of a solid lipid matrix and a liquid lipid [13]. They have several 61 
desirable advantageous such as low toxicity of constituents, and the ability to protect the 62 
incorporated drug from degradation by immobilization in the solid/liquid particle matrix [14]. 63 
Moreover, NLCs have overcome problems associated with SLNs, including limited drug loading, 64 
risk of gelation, and drug leakage during storage caused by lipid polymorphism [14].  65 
Fluconazole (FLZ), a first-generation triazole, is a broad-spectrum anti-fungal agent that inhibits 66 
cytochrome P450-dependent 14α-lanosterol demethylation, a vital step in cell membrane 67 
ergosterol synthesis [15]. Fluconazole is active against all Candida species except for C. 68 
glabrata, which has acquired resistance to fluconazole, and C. krusie, which is resistant to the 69 
drug intrinsically [16, 17]. Despite its advantageous pharmacological activity, FLZ can cause 70 
several clinically significant side effects, including headache, hives, itching or skin rash, 71 
abdominal pain, and hematemesis [3]. While the prevalence and severity of side effects may be 72 
decreased by lowering the dose of FLZ, clinical efficacy may be reduced and resistance 73 
increased through this approach. This problem is important because FLZ is currently used for 74 
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both prophylaxis and the treatment of broad spectrum infections of candidiasis, yet, the 75 
emergence of drug-resistant isolates continues to increase dramatically [18-20]. In response to 76 
this challenge, the use of new drug formulations and drug delivery systems to reduce resistance 77 
while maintaining or increasing clinical efficacy are urgently needed [21] [22]. While there is 78 
limited evidence regarding the effectiveness of FLZ loaded NLCs (FLZ-NLC) [1] on Candida 79 
albicans, the activity of FLZ-NLCs against a broad range of Candida species, including C. 80 
glabrata and C. krusie, has not yet been studied. To this end, the purpose of the present study 81 
was to estimate the clinical efficacy of FLZ-NLCs on FLZ-resistant strains of certain Candida 82 
species.  83 
 84 
2. Materials and Methods 85 
2.1 Materials 86 
Fluconazole (FLZ, Pharmaceutica grade) was obtained from Arasto Pharmaceuticals 87 
Chemicals Inc. (Tehran-Iran). Compritol® 888 ATO (CO), Lipocire and Precirol® ATO 5 88 
were supplied from Gattefossé (Saint-Priest, Cedex, France). Sabouraud dextrose agar 89 
(SDA), RPMI medium, stearic acid (SA), Oleic acid, Tween 80 (Tn80), Span 60 (Sn60) and 90 
Span 80 (Sn80) were purchased from Merck Co. (Germany). HPLC grade acetonitrile and 91 
methanol were supplied by the Merck (Germany). Morpholinepropanesulfonic acid (MOPS) 92 
was purchased from Sigma Chemical Co., St. Louis, MO (USA). Deionized water was 93 
purified using a Milli-Q system (Millipore, Direct-Q). All other reagents and solvents were 94 
either of analytical or high-performance liquid chromatography (HPLC) grades. 95 
 96 
2.2. Screening of lipids 97 
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In order to determine the maximum amount of drug a lipid can hold, it is necessary to estimate 98 
the solubility of the given drug in the lipid. To accomplish this goal, we evaluated the solubility 99 
of FLZ 25 %w/w  in melted Compritol® 888 ATO, Lipocire, Precirol® ATO 5  and stearic acid 100 
(SA) (Merck, Germany). The solubility of FLZ was also assessed in melted solid lipid combined 101 
with oleic acid as a liquid lipid, in ratios of 90:10, 80:20 and 70:30. The lipid mixtures were 102 
stirred at 200 revolutions per minute for 10 minutes at 85°C, using a hot plate magnetic stirrer 103 
(Unimax 1010, Heidolph, Germany). When the drug was dissolved in lipids with different 104 
concentrations, they were examined for the presence of the drug crystals in the lipid matrix to 105 
explore which lipids or lipid combinations were able to dissolve the drug completely. 106 
2.3. Preparation of formulation 107 
FLZ-NLCs were prepared and optimised via a process utilising an ultrasonic probe. The method 108 
has been adopted from the previously reported studies in the literature [10]. To prepare NLCs, a 109 
carrier lipid in its solid form (stearic acid/ Compritol® 888 ATO) was melted at 85 °C in 110 
combination with liquid lipid (oleic acid) and a lipophilic surfactant (Span 80) based on the 111 
proportion in Table 2. The molten lipid phase was dispersed in a 1/3 of the aqueous solution of 112 
hydrophilic surfactant  prepared by weighing out 0.84 % w/w Tween 80 at the same temperature 113 
and sonicated by using a probe sonicator (Bandelin sonopuls, Berlin, Germany) for 5 min (Model 114 
HD 3200, Prob TT25, 50% power and 14.28 KJ, continuous) to form a pre-emulsion. At the end 115 
of the sonication, the mixture was dispersed into the remaining 2/3 of the hydrophilic surfactant 116 
solution maintained in an ice bath. The final mixture was sonicated again for 10 min (50 % 117 
power and 43.21 KJ) whilst still immersed in the ice-bath (Table 2). 118 
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FLZ-loaded NLCs were prepared using the probe ultrasonication method, which has been used 119 
previously in the production of lipid nanoparticles [10]. Briefly, solid lipid either alone or in 120 
combination with oleic acid and Span 80 (Sn80) (Merck, Germany) were melted at 85°C. FLZ 121 
was then added to the lipid and the mixture was stirred until the drug was completely dissolved. 122 
An aqueous phase composed of deionized water and Tween 80 (Tn80) at 85°C was added to the 123 
lipid phase using Ultra-Turrax® (IKA, Heidelberg, Germany),  a high-shear stress homogenizer, 124 
for 5 minutes at 10,000 revolutions per minute. The heated mixture was then sonicated (Bandelin 125 
Sonopuls, Berlin, Germany) for 5 minutes. At the end of the sonication, the mixture was 126 
dispersed into an ice-cold surfactant solution maintained in an ice bath. The final mixture was 127 
sonicated again for 10 minutes while immersed in the ice-bath to promote the formation of the 128 
lipid nanoparticles (Table 2). 129 
2.4. Characterization of the nanoparticles 130 
2.4.1. Morphology 131 
In order to determine the shape of FLZ-NLCs, transmission electron microscopy (accelerating 132 
voltage 100kV; TEM, CM 30, Phillips, Netherlands) was used. First, the NLC samples were 133 
diluted two times with distilled water. One drop of the diluted sample was placed on a 200-mesh 134 
carbon-coated copper grid, stained with 2 % phosphotungstic acid solution and dried at room 135 
temperature. Representative images of the sample were reported.  136 
 137 
 138 
2.4.2. Particle size and zeta potential 139 
Photon correlation spectroscopy (PCS) with a Malvern Zetasizer ZS (Nano ZA, Malvern 140 
Instruments, UK) was used to determine the particle size, and to profile the size distribution 141 
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(polydispersity index, PDI) and zeta potential of the nanoparticles. In this method, the sample 142 
was measured at 25 °C with an angle detection of 90°. The concentration of the samples for 143 
analysis on the Zetasizer was 20-400 kilocounts per second (KCPS) and the intensity of 144 
diffraction was 100,000 counts per second.  145 
 146 
2.4.3. High-performance liquid chromatography (HPLC) analysis of fluconazole 147 
The HPLC assay was performed using an Agilent 1100 chromatograph, equipped with the 148 
Agilent Eclipse XDB-C18 column (5 µm, 4.6 mm × 250 mm). The mobile phase was composed 149 
of 10 mM sodium acetate buffer (adjusted to pH 5.0 with glacial acetic acid) and methanol 150 
(65:35) with a flow rate of 1 ml/minute.  151 
2.4.4. Determination of fluconazole entrapment efficiency 152 
Entrapment efficiency (EE%) was determined to assess the extent of FLZ incorporation in the 153 
nanoparticles by measuring the concentration of the free unloaded FLZ in the aqueous phase of 154 
the nanoparticle suspension. To determine the entrapment efficiency (EE%) of FLZ in the NLCs, 155 
the FLZ-NLCs were subjected to centrifugation for 20 minutes at 25,000 rpm (HERMLE, 156 
Z36HK, Germany) and filtered (pore size: 0.22 µm). The amount of drug in the supernatant was 157 
determined by HPLC and the experiment was conducted in triplicate. 158 
The drug entrapment efficiency (EE%) was calculated from Equation 1, where Wi and Wf were 159 
the amount of drug added in the formulation and amount of drug in the supernatant, respectively. 160 
1) (Eq.100% 


Wi
WfWi
EE  161 
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2.5. Drug release measurement  162 
The release of FLZ was estimated using the dialysis tube technique. To determine the release rate 163 
of FLZ from the nanoparticles, 5 ml of the prepared dispersion was poured into a dialysis bag 164 
using a cut-off of 12,500 Daltons, with the two ends fixed by clamps. The bag was then dropped 165 
into 500 ml of simulated intestinal fluid at a pH of 6.8 and stirred with a magnetic stirrer at 60 166 
revolutions per minute at 37.0 ± 0.1°C. Samples were withdrawn at predetermined time intervals 167 
of 30 min and 1, 2, 4, 6, 8 and 24 hours, and replaced with fresh simulated intestinal fluid 168 
maintained at the same temperature. Samples of 1.5 ml were withdrawn, centrifuged for 30 169 
minutes at 25,000 revolutions per minute, filtered with a 0.22 µm filter, and directly injected into 170 
the HPLC system. 171 
2.6. Antifungal susceptibility testing for fluconazole-loaded nanostructure lipid 172 
carriers 173 
2.6.1. Isolates 174 
To assess the effectiveness of NLCs containing FLZ, we applied FLZ-NLCs against 90 clinical 175 
Candida isolates as a means of protecting the drug binding sites. All strains were originally 176 
isolated from Iranian patients suffering from cutaneous and sub-cutaneous candidiasis (all C. 177 
albicans and C. parapsilosis strains were vaginal isolates; the rest of Candida strains were 178 
isolated from vagina, bronchoalveolar lavage, sputum, and nail) and were identified to the 179 
species level by a polymerase chain reaction-restriction fragment length polymorphism (PCR-180 
RFLP) analysis using an Msp1 restriction enzyme [23]. Resistant strains were proven to be 181 
resistant against FLZ (data not shown) by using standard protocol CLSI documents M27-A3 and 182 
M27-S4. Stock cultures were initially grown on yeast extract peptone dextrose agar (YEPD; 1% 183 
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yeast extract, 2% Bacto Peptone, 2% dextrose) at 35°C for 48 hours to obtain fresh viable yeast 184 
cells. To perform antifungal susceptibility testing, the isolates were inoculated onto Sabouraud 185 
dextrose agar (SDA; supplied by Merck, Germany) and incubated at 35°C for 24 hours.  186 
 187 
2.6.2. Antifungal agents 188 
Antifungal susceptibility testing (AFST) was performed with FLZ, as well as FLZ-NLCs. 189 
Fluconazole (Arasto Pharmaceuticals Chemicals Inc., Iran) was dissolved in sterile water, and a 190 
two-fold dilution was prepared in Roswell Park Memorial Institute (RPMI) 1640 medium (with 191 
L-glutamine, without bicarbonate) (Merck, Germany) and buffered to pH 7.0 using a 0.165 M 192 
solution of 3-N-morpholinepropanesulfonic acid (MOPS; Sigma Chemical Co., St. Louis, MO). 193 
Two-fold dilutions of FLZ-NLC were prepared with equal concentrations of FLZ such that 16 194 
µg/ml to 0.1 µg/ml.  FLZ-SLNs were freshly synthesized and applied for AFST for one week 195 
afterward.  196 
 197 
2.6.3. Antifungal susceptibility testing 198 
A minimum inhibitory concentration (MIC) against both FLZ and FLZ-NLCs was determined 199 
according to recommendations confirmed in the CLSI M27-A3 and M27-S4 documents [24, 25]. 200 
FLZ and FLZ-NLCs were dispensed into 96-well microdilution trays at a final concentration of 201 
0.063–64 g/ml and 0.1–8% (0.1–8 g/ml), respectively. Candida blastospore suspensions were 202 
prepared from isolates grown for 24 hours. Yeast colonies were suspended in sterile saline 203 
solution and spectrophotometrically adjusted at 530 nm to optical densities (OD) from 0.09 to 204 
0.13 (absorbance at 530 nm ranging from 0.09 to 0.13 is equal to transmission of 75–77%). The 205 
final size of the stock inoculums ranged from 1 × 106 to 5 × 106 CFU/ml. A working suspension 206 
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was then made using a 1:10 dilution followed by a 1:100 dilution of the stock suspension with 207 
RPMI medium, which resulted in two times test inoculums (1 × 103 to 5 × 103 CFU/ml). 208 
Microdilution plates were incubated at 35°C and examined visually after 24 and 28 hours as the 209 
concentration of drug that elicited significant inhibition (approximately 50%) of growth 210 
compared with a drug-free control. In the case of FLZ-loaded NLCs, results were examined 211 
using an inverted microscope (Motic AE31, Hong Kong, China), due to its self-turbidity. C. 212 
parapsilosis (ATCC 22019) was chosen as the quality control to be used with each new series of 213 
MIC plates. 214 
 215 
2.7. Statistical analysis 216 
All of the results were expressed as the mean ± standard deviation. The groups were compared 217 
by an analysis of variance (ANOVA) following Dunnett’s test. In order to determine if FLZ-218 
NLCs could significantly decrease the MIC values, a statistical analysis of the results was 219 
performed using the Mann-Whitney U test for studying the differences between the MICs of 220 
susceptible and resistant Candida isolates and the Kruskal–Wallis test for three groups of 221 
Candida strains (C. albicans, C. parapsilosis and C. glabrata). The differences were considered 222 
statistically significant at P < 0.05. The statistical analysis was performed using SPSS (V18). 223 
 224 
 225 
Results and Discussion 226 
2.8. Screening of lipids 227 
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After evaluating the solubility of FLZ in the lipids, four lipids with different physicochemical 228 
properties were selected for the formulation of lipid nanoparticles, as listed in Table 1. Since no 229 
drug crystals were observed when FLZ and Compritol® 888 ATO or stearic acid were heated 230 
together (for all solid lipid:liquid lipid ratios), Compritol® 888 ATO and stearic acid were 231 
selected for production of NLCs. In contrast, FLZ was not completely soluble in the other lipids 232 
listed in Table 1. 233 
 234 
2.9. Characterization of SLNs 235 
The particle sizes, zeta potential, and entrapment efficiency of the developed SLNs and NLCs 236 
are shown in Table 2. The FLZ-NLC-6 was selected as the best formulation because of its small 237 
particle size (126.4 ± 15.2 nm), relatively high zeta potential (-35.1 ± 3.0) and good EE% (93.6 ± 238 
3.5) (P < 0.05). Furthermore, it was observed that the average particle size decreased with an 239 
increase in the concentration of oleic acid (P < 0.05) however there wasn’t a significant 240 
difference between the two lipids in cases of zeta potential and PDI. These results were in 241 
agreement with previously reported studies which an increase in the liquid phase (oleic acid) in 242 
the formulations reduced the viscosity of the NLC suspensions and thus the particle size 243 
decreased [26]. Yuan et al. indicated that no obvious change in particle size was found when the 244 
oleic acid content in NLC was increased [27]. The solubility of the drug in the liquid lipid could 245 
probably be considered as another key factor for the reduction in particle size.  246 
 It has also been reported that the concentration of oleic acid had no significant effect on NLC 247 
particle size [28]. The phenomenon for zeta potential can be explained by the fact that oleic acid 248 
is negatively charged at its carboxylic groups. Thus, NLC-3 revealed the highest zeta potential 249 
values, possibly due to the accumulation of oleic acid at the surface of the nanoparticles [28]. It 250 
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is clear that the drug entrapment efficiency rose with increasing percentages of oleic acid (Table 251 
2) (P > 0.05). This observation corresponds with findings that the incorporation of liquid lipids 252 
to solid lipids could leave enough space to accommodate drug molecules, thus, leading to 253 
improved drug entrapment efficiency [26]. The higher solubility of FLZ in liquid lipid could be 254 
another factor for the improvement of entrapment efficiency. Last, the TEM micrographs of the 255 
FLZ-NLC revealed that the FLZ-NLC particles are spherical in nature (the figure is not shown).  256 
 257 
2.10. In vitro release study 258 
The drug release profile of the FLZ-NLCs is shown in Figure 1A. In this study, the FLZ-NLCs 259 
showed burst-release behavior during the first 30 minutes (the initial stage), followed by a 260 
sustained release pattern. The burst release in the early stage could be due to the diffusion of the 261 
unencapsulated drug on the NLC surface and thereafter from the core. Hu et al. showed that the 262 
release rate at the initial stage increased with the increasing oleic acid content in nanoparticles 263 
and that this phenomenon is dependent on the homogeneity of the mixture of liquid and solid 264 
lipids during the NLC preparation [26].  265 
 266 
 267 
 268 
2.11. Antifungal susceptibility testing 269 
Using the CLSI document M27-A3 susceptibility testing methodology, the development of most 270 
strains of Candida species was clearly visible after 24 hours of incubation at 35°C. However, the 271 
results were interpreted after 48 hours of incubation at 35°C, as CLSI recommended. Out of 90 272 
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isolates, 39 isolates demonstrated high MIC values (≥64 µg/ml) against FLZ (Table 3 and Figure 273 
2), among which, 14 isolates were C. albicans (35%), 13 were C. glabrata (33%), 9 were C. 274 
parapsilosis (23%), and 3 were C. krusei (7.7%). No statistically significant differences were 275 
seen among MICs for FLZ-susceptible Candida species. Table 3 depicts the results for the in 276 
vitro antifungal susceptibility profile of FLZ-NLCs against FLZ-susceptible isolates. 277 
Specifically, we found that using the new formulation of FLZ-NLCs leads to a statistically 278 
significant decrease in MIC values (P < 0.05). C. albicans isolates showed more susceptibility 279 
against FLZ-NLCs than C. glabrata or C. parapsilosis (P < 0.05). Furthermore, the MIC50 drug 280 
concentration was obtained as 0.031, 0.15, and 0.15 μg/ml for C. albicans, C. parapsilosis and C. 281 
glabrata, respectively. Table 4 shows details of the MIC for resistant strains of all species. FLZ-282 
resistant strains behaved as susceptible ones after being treated with new formulations, such that 283 
their MIC values were in the susceptible range.  284 
 285 
The MIC50 drug concentration was obtained as 0.0625 , 0.031 and 0.25 μg/ml for FLZ-resistant 286 
strains of C. albicans, C. glabrata and C. parapsilosis, respectively. Comparing the results for 287 
two susceptible and resistant groups, FLZ-NLCs were significantly more effective on FLZ-288 
susceptible C. albicans and C. glabrata isolates. However, the activity of FLZ-NLCs was not 289 
statistically significantly different for C. parapsilosis strains (P > 0.05). Overall, FLZ-NLCs 290 
resulted in a significant decrease in MIC (P < 0.05). 291 
 292 
To the best of our knowledge, there are few documented reports about the synthesis of FLZ-293 
NLCs. Thus, studying their effect on a large number of Candida species is novel. The small size 294 
of the lipid particles in the NLCs helps ensure close contact with the target tissue and may 295 
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enhance the penetration of drugs [29] Moreover, the size of lipid matrices may also enable 296 
sustained drug release [30, 31]. Nanostructured lipid carriers have been developed to overwhelm 297 
the drawbacks associated with SLNs. In contrast with SLNs, NLCs show a higher loading 298 
capability for compounds, since blending a liquid lipid with the solid lipid results in a higher 299 
element drug stacking. Additionally, NLCs allow the release of the drug to be controlled and 300 
increase the chemical stability of the incorporated drugs. Furthermore, NLCs are protected 301 
carriers, which can be produced easily on a large scale [14, 32-34]. 302 
 303 
According to our results, the MICs of FLZ were significantly decreased when FLZ-NLCs were 304 
used; suggesting that the therapeutic dose and risk of adverse drug effects may be decreased. One 305 
possible explanation for these antifungal susceptibility results is the mechanism responsible for 306 
the drug resistance recognized in pathogenic fungi [35, 36]. The overexpression of plasma 307 
membrane transport proteins that pump azoles out of cells is a frequent mechanism of high-level 308 
azole resistance in fungi, thereby reducing the intracellular azole concentrations below the levels 309 
at which Erg11p is inhibited [37, 38]. Knowing the conformations of the efflux pumps may lead 310 
to the design of novel formulation/drug delivery systems for azole drugs in order to keep the 311 
drug away from the efflux pumps [39]. Therefore, description of the architecture of drug-binding 312 
sites in ABC transporters is essential to understand the drug-protein interactions. This knowledge 313 
will also contribute to understanding the design of specific inhibitors or suitable shields to 314 
prevent drug-protein interactions. In this study, FLZ-NLCs provided an effective nanoscaled 315 
safeguard that protects the drug from being pumped out by transporter proteins. Moreover, the 316 
hydrophobic surface of FLZ-NLCs may lead to the drug entering the yeast cells more efficiently. 317 
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Since there is an increasing trend in emerging the azole-resistant fungal isolates, it would be a 318 
great idea to assess the new delivery system for other azoles such as voriconazole. 319 
 320 
3. Conclusions: 321 
In this study, we evaluated a novel delivery system for combating several Candida strains that 322 
exhibit different susceptibility to a conventional formulation of FLZ. An FLZ-loaded NLC 323 
consisting of stearic acid was successfully prepared by probe ultrasonication technique. Novel 324 
drug formulations may avoid drug recognition by efflux pump proteins, keeping the drug away 325 
from transporters. This study was the first to report the effectiveness of FLZ-NLCs as alternative 326 
delivery systems for FLZ on Candida isolates in vitro. However, studies on the efficacy of the 327 
new formulation are recommended for future works in vivo. Moreover, the assessment of the 328 
stability of synthesized FLZ-NLCs is a challenging issue which may address this question 329 
whether this formulation is suitable through topical, oral or systemic use or not. 330 
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Figure 1. In vitro release of FLZ-NLCs 6 (n = 3; P ≤ 0.05) 454 
 455 
 456 
 457 
 458 
 459 
 460 
 461 
 462 
 463 
 464 
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 466 
Figure 2: Comparison between the numbers of isolates at each reported MICs of susceptible 467 
strains while treating with FLZ and FLZ-NLCs (fig 3a). Fig 3b shows the number of isolates 468 
reported at each MIC in FLZ-resistant Candida species. Using FLZ-NLCs, susceptible isolates 469 
(3a) showed a significant decrease in MIC values (P value < 0.05). Moreover, resistant isolates 470 
(3b) shows increased susceptibility against FLZ-NLCs in such a way as to be placed in the 471 
susceptible range [25]. 472 
 473 
  474 
 475 
 476 
 477 
 478 
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Table 1. Screening of lipids based on solubility of FLZ 480 
Lipid 25 mg FLZ/100mg Solid: liquid lipid 
 100:00 90:10 80:20 70:30 
Compritol® 888 ATO + + + + 
Lipocire - - - + 
Precirol® ATO 5 - - + + 
Stearic acid + + + + 
 481 
 482 
 483 
Table 2. Component and physicochemical properties of investigated FLZ-loaded SLN and NLC (% w/w). 484 
 485 
 FLZ CO SA OA Sn80 Tn80 PS PI ZP EE% 
NLC1 0.5 1.8 - 0.2 1.25 2.5 165.0±19.9 0.134±0.010 -28.1±2.6 89.1±6.3 
NLC2 0.5 1.6 - 0.4 1.25 2.5 158.0±12.9 0.221±0.010 -31.6±2.6 91.7±4.2 
NLC3 0.5 1.4 - 0.6 1.25 2.5 148.0±13.9 0.134±0.010 -33.6±2.6 92.3±1.3 
NLC4 0.5 - 1.8 0.2 1.25 2.5 188.0±11.1 0.260±0.050 -27.3±1.8 90.0±2.6 
NLC5 0.5 - 1.6 0.4 1.25 2.5 140.2±19.3 0.203±0.011   -29.1±4.3 92.0±2.6 
NLC6 0.5 - 1.4 0.6 1.25 2.5 126.4±15.2 0.225±0.012 -35.1±3.0 93.6±3.5 
CO: Compritol® 888 ATO; SA: Stearic acid; OA: Oleic acid; Sn80: Span80; Tn80: Tween80. 486 
 487 
 488 
 489 
 490 
 491 
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 492 
 Table 3. Effect of new delivery system of FLZ on FLZ-susceptible and FLZ-resistant strains of some common Candida isolates 493 
Isolates 
Number 
(n) 
Antifungal 
agent 
MIC 
MIC range MIC50 MIC90 GM Mode 
≥64 32 16 8 4 2 1 0.5 0.25 0.125 0.062 0.031 ≤0.015 
 
C. albicans 
20 (S) 
FLZ - - - - - 2 3 13 2 - - - - 0.25-2 0.5 1.1 0.594604 0.5 
FLZ-NLC - - - - - - - - - 2 6 9 3 0.125-0.015 0.031 0.075 0.039444 0.031 
17 (R) 
FLZ 14 - 1 2 - - - - - - - - - 8-64 - - - - 
FLZ-NLC - - - - - - - - 1 3 5 4 1 0.015-0.25 0.062 0.125 0.059172 0.062 
 C. glabrata 
16 (S) 
FLZ - - - 6 6 1 2 - 1 - - - - 0.25-8 4 8 5.656854 8 
FLZ-NLC - - - - - - - - - 1 - 1 14 0.015-0.0125 0.015 0.015 0.015518 0.015 
13 (R) 
FLZ 13 - - - - - - - - - - - - - - - - - 
FLZ-NLC -- - - - - - - - - 2 - 5 6 0.015-0.125 0.015 0.106 0.023019 0.015 
 C. parapsilosis 
9 (S) 
FLZ - - - - - 3 1 2 3 - - - - 0.25-2 0.5 2 1 2 
FLZ-NLC - - - - - - - - - - - - 9 - 0.015 0.015 0.015 0.015 
9 (R) 
FLZ 9 - - - - - - - - - - - - - - - - - 
FLZ-NLC - - - - - - - - 1 - - - 8 0.015-0.25 0.015 0.062 0.020505 0.015 
 C. tropicalis (S) 2 
FLZ - - - - - - - 1 1 - - - - 0.25-0.5 - - - - 
FLZ-NLC - - - - - - - - - - 1 - 1 0.015-0.062 - - - - 
 C. kefyre (S) 2 
FLZ - - - - - - - 2 - - - - - - - - - - 
FLZ-NLC - - - - - - - - - - - - 2 - - - - - 
 C. krusei (R) 
3 FLZ 2 1 - - - - - - - - - - - - - - - - 
 FLZ-NLC - - - - - - - - - 1 1 - 1 0.015-0.125 - - - - 
 494 
*GM: geometric mean MIC. 495 
** FLZ: fluconazole, FLZ_NLC: fluconazole loaded Nanostructured Lipid Carrier 496 
